# Randomized ESRD Trial COmparing CBT alone VERsus with buprenorphine (RECOVER)

> **NIH NIH U01** · UNIVERSITY OF WASHINGTON · 2022 · $621,362

## Abstract

PROJECT SUMMARY/ABSTRACT
Over 60% of patients with kidney failure treated with long-term hemodialysis report chronic pain from highly
prevalent musculoskeletal and neuropathic conditions. No clinical trial thus far has tested the efficacy and
safety of treatments to manage chronic pain in this population. As such, the rate of opioid prescribing for
people undergoing maintenance hemodialysis is 2-4 times higher than for the general population despite the
significahtly higher risk for adverse events. The HEAL Initiative HOPE trial is a randomized controlled clinical
trial designed to test the efficacy of pain coping skills training (PCST) to reduce pain interference and opioid
prescribing for patients undergoing long-term hemodialysis. The HOPE trial seeks to enroll 640 participants
from eight Clinical Centers composed of 16 enrolling sites; 327 participants have been enrolled to date. The
consortium has successfully engaged patients from the outset and this has helped enroll a high proportion of
Black and Latino participants. But major gaps remain in enrolling several key sub-groups. The trial is delivering
the PCST intervention via telehealth; low motivational readiness and technology proficiency in many patients
are posing as barriers to enrollment. Kidney failure disproportionately affects the elderly and those with
physical and visual disabilities, sub-groups with high mobile health hesitancy and lower research participation.
The current trial infrastructure also does not allow us to reach out to American Indian populations and rural
communities, sub-groups with high prevalence of kidney failure and opioid prescribing. To bridge these gaps
and ensure externally valid inferences, the University of Washington Clinical Center (sites in Albuquerque, NM,
New York, NY, and Seattle, WA), the Scientific Data and Research Center (SDRC), and HOPE Trial Patient
Advisory Group are requesting supplemental funds to enhance enrollment of three sub-groups of individuals –
(1) those with mobile health hesitancy; (2) American Indians living in rural communities near Albuquerque, New
Mexico; and (3) the geographically isolated community on the Kitsap and Olypmic Peninsulas near Seattle.
The proposed strategies are responsive to the NOSI as we plan to (1) develop strategies to promote inclusion
in HOPE, a study using digital interventions; (2) develop and disseminate study materials that are (digital)
health literacy appropriate; (3) have culturally competent patient coordinators to facilitate outreach to and
enrollment of American Indians; and (4) provide outreach to and accommodate patients with diverse travel
needs such as those in remote communities. Importantly, the proposed work will accomplish its goals without
increasing burden to the primary study. The SDRC will disseminate the educational materials to overcome
mobile health hesitancy to all the 16 enrolling sites. The outreach efforts to American Indian communities and
the Kitsap and Olympic Peninsulas ...

## Key facts

- **NIH application ID:** 10614763
- **Project number:** 3U01DK123786-01S1
- **Recipient organization:** UNIVERSITY OF WASHINGTON
- **Principal Investigator:** Daniel Cukor
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $621,362
- **Award type:** 3
- **Project period:** 2022-06-01 → 2024-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10614763

## Citation

> US National Institutes of Health, RePORTER application 10614763, Randomized ESRD Trial COmparing CBT alone VERsus with buprenorphine (RECOVER) (3U01DK123786-01S1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10614763. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*